| pubmed-article:18838256 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18838256 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:18838256 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:18838256 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
| pubmed-article:18838256 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:18838256 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:18838256 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:18838256 | lifeskim:mentions | umls-concept:C0392752 | lld:lifeskim |
| pubmed-article:18838256 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:18838256 | pubmed:dateCreated | 2008-11-10 | lld:pubmed |
| pubmed-article:18838256 | pubmed:abstractText | Most men with low-risk localised prostate cancer prefer treatments with high control rates and minimal disruption to their lives. Hypofractionating external radiation treatments can theoretically maintain high bioequivalent tumour doses, decrease treatment visits and decrease acute and late toxicities. The aim of this study was to assess the toxicity and feasibility of a hypofractionated accelerated regimen for these patients. | lld:pubmed |
| pubmed-article:18838256 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18838256 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18838256 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18838256 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18838256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18838256 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18838256 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:18838256 | pubmed:issn | 0936-6555 | lld:pubmed |
| pubmed-article:18838256 | pubmed:author | pubmed-author:MortonGG | lld:pubmed |
| pubmed-article:18838256 | pubmed:author | pubmed-author:CheungPP | lld:pubmed |
| pubmed-article:18838256 | pubmed:author | pubmed-author:PanaII | lld:pubmed |
| pubmed-article:18838256 | pubmed:author | pubmed-author:GardnerSS | lld:pubmed |
| pubmed-article:18838256 | pubmed:author | pubmed-author:CardosoMM | lld:pubmed |
| pubmed-article:18838256 | pubmed:author | pubmed-author:HolderHH | lld:pubmed |
| pubmed-article:18838256 | pubmed:author | pubmed-author:LoblawD ADA | lld:pubmed |
| pubmed-article:18838256 | pubmed:author | pubmed-author:TironaRR | lld:pubmed |
| pubmed-article:18838256 | pubmed:author | pubmed-author:TanoC ACA | lld:pubmed |
| pubmed-article:18838256 | pubmed:author | pubmed-author:BasranP SPS | lld:pubmed |
| pubmed-article:18838256 | pubmed:author | pubmed-author:CestaAA | lld:pubmed |
| pubmed-article:18838256 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18838256 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:18838256 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18838256 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18838256 | pubmed:pagination | 729-37 | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:meshHeading | pubmed-meshheading:18838256... | lld:pubmed |
| pubmed-article:18838256 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18838256 | pubmed:articleTitle | Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. | lld:pubmed |
| pubmed-article:18838256 | pubmed:affiliation | Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. | lld:pubmed |
| pubmed-article:18838256 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18838256 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18838256 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:18838256 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18838256 | lld:pubmed |
